Meeting
2023 ASCO Annual Meeting
Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC).
Authors
William Joseph Chapin
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA
William Joseph Chapin , Wei-Ting Hwang , Ronac Mamtani , Mark H. O'Hara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3574)
DOI
10.1200/JCO.2023.41.16_suppl.3574
Abstract #
3574
Poster Bd #
274
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2023 ASCO Annual Meeting
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).
First Author: Haeseong Park
Poster
2016 Gastrointestinal Cancers Symposium
Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the GERCOR index.
First Author: Osamu Muto
Poster
2016 Gastrointestinal Cancers Symposium
REOX: Effectiveness evaluation of re-exposure to oxaliplatin in patients with metastatic colorectal cancer.
First Author: Talita Gonzaga Costa